Published 11/03/2009 by FinanzNachrichten.de
SCYNEXIS' SCY-635 Demonstrates Positive Antiviral Activity in Combination with Approved and Investigational Anti-HCV Agents
--In Vitro Results presented in a poster session at AASLD; Phase 2 combination studies to be initiated in 2Q 2010--
Drug discovery company SCYNEXIS, Inc. today presented positive data from an in vitro study evaluating the antiviral activity of SCY-635 in combination with...
Share this
What others report on the same story